$36.32
▼ -0.0% Today
as of Sep 4, 16:55 ET
Last 30 days
Recent Press Releases & News
mixed
▲ 3
● 21
▼ 1
S&P Global Ratings Upgrades Teva Pharmaceutical to 'BBB-'
Teva (TEVA) Backed a Bid of Up to $125M in Cash Plus Assumed Liabilities for BioXcel’s Assets. Is Bankruptcy-Sale Risk Worth the At-Home Opportunity?
S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
Overview
52-week range
$18
$38
90% of range
Avg surprise (last 2)
+5.5%
Avg reaction (last 1)
+9.2%
100% positive
Latest IV / EM
64%
EM ±2.7% · $37 · Sep 4
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.49 | — | — | — | — | financials |
| Tue Mar 31, 2026 | Mar 2026 | $0.31 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $0.37 | — | — | — | — | financials |
| Wed Jul 30, 2025 | Jun/2025 | $0.64 | $0.60 | +6.7% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $0.49 | $0.47 | +4.3% | — | +9.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.39 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.75 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.12 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.06 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.78 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.20 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.14B | $3.98B | — | $4.48B | $4.18B | $3.89B | — | $4.33B |
| Cost of revenue | $1.99B | $2.01B | — | $2.18B | $2.07B | $2.01B | — | $2.18B |
| Gross profit | $2.15B | $1.97B | — | $2.30B | $2.10B | $1.88B | — | $2.15B |
| Operating income | $-231M | $652M | — | $882M | $455M | $519M | — | $-51M |
| Net income | $-576M | $369M | — | $433M | $282M | $214M | — | $-437M |
| EPS (diluted) | $-0.49 | $0.31 | — | $0.37 | $0.24 | $0.18 | — | $-0.39 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.65B | $3.74B | $3.56B | $2.20B | $2.16B | $1.70B | $3.30B | $3.32B |
| Inventory | $3.22B | $3.18B | $3.18B | $3.32B | $3.50B | $3.25B | $3.01B | $3.96B |
| Total current assets | $13.76B | $13.71B | $13.95B | $12.74B | $12.62B | $11.53B | $12.55B | $12.31B |
| Total assets | $39.86B | $40.04B | $40.75B | $39.86B | $40.13B | $38.41B | $39.33B | $41.76B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $32.10B | $31.81B | $32.83B | $32.60B | $33.30B | $32.15B | $33.61B | $35.38B |
| Total equity | $7.75B | $8.23B | $7.91B | $7.25B | $6.83B | $6.27B | $5.37B | $6.38B |